Anogenital warts (HPV)
HPV warts · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Anogenital warts are caused by low-risk human papillomavirus types (6/11). They are benign but recurrent; treatment is cosmetic/symptomatic. Vaccination prevents them and the high-risk types causing cancer.
Red flags
- Pigmented, indurated, ulcerated or bleeding lesion (neoplasia)
- Rapid growth or treatment resistance
- Immunosuppression with extensive disease
- Obstructive internal/urethral lesions
- Lesions in a child raising safeguarding concern
Assessment
Differential diagnosis
- Condylomata lata of secondary syphilis
- Molluscum contagiosum
- Skin tags / pearly penile papules
- Intraepithelial neoplasia
- Seborrhoeic keratosis
Investigations
- Clinical diagnosis by inspection
- Full STI screen including HIV and syphilis
- Biopsy if atypical, pigmented, bleeding or treatment-resistant
- Proctoscopy/speculum exam if internal lesions suspected
- Cervical screening per programme
- Consider anal cytology/HRA in high-risk groups
Management
- Confirm diagnosis clinically; biopsy atypical lesions
- Screen for coexisting STIs and HIV
- Discuss treatment options and that they clear virus-driven lesions, not infection
- Offer patient-applied topical therapy or clinic-based ablative treatment
- Avoid podophyllotoxin/imiquimod in pregnancy; use physical ablation instead
- Treat according to number, site and keratinisation of lesions
- Counsel on recurrence, transmission and condom limitations
- Offer HPV vaccination where eligible
- Arrange cervical/anal screening as indicated
- Review response and switch modality if poor clearance
- Address psychosexual concerns
- Encourage partner awareness (routine screening, not treatment of warts)
Drugs & doses
Imiquimod 5% cream applied 3 times weekly, washed off after 6-10 h, up to 16 weeks
Podophyllotoxin 0.5% solution/0.15% cream twice daily for 3 days then 4 days off, up to 4-6 cycles
Cryotherapy with liquid nitrogen (clinic, repeated weekly)
Trichloroacetic acid 80-90% applied in clinic
HPV vaccine (9-valent) per schedule for prevention
Disposition
Outpatient sexual health/dermatology; routine; refer atypical lesions for biopsy.
Complications & pitfalls
- Recurrence after treatment
- Local skin reaction/scarring from therapy
- Psychological distress
- Rare giant condylomata (Buschke-Lowenstein)
- Associated high-risk HPV intraepithelial neoplasia
Exam pearls
- Warts are low-risk HPV; cancers arise from high-risk types (16/18)
- Vaccination prevents both warts and HPV-related cancers
- No single treatment is clearly superior; tailor to patient and lesion
- Treating warts does not eliminate HPV or guarantee no transmission
- Avoid imiquimod/podophyllotoxin in pregnancy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.